动脉粥样硬化：肠道微生物组与动脉粥样硬化的关联。
Atherosclerosis: Association between the gut microbiome and atherosclerosis.
机构信息
Departments of Microbiology, Medicine, and Human Genetics, University of California Los Angeles, Los Angeles, California 90095-1679, USA.
出版信息
Nat Rev Cardiol. 2017 Dec;14(12):699-700. doi: 10.1038/nrcardio.2017.169. Epub 2017 Nov 3.
Abstract
The gut microbiota has been associated with many different disorders, including cardiovascular diseases. A new study by Jie and colleagues is the first large case–control study to examine directly the enrichment of certain communities of gut bacteria in patients with atherosclerotic cardiovascular disease compared with control individuals.
摘要
肠道微生物群与许多不同的疾病有关，包括心血管疾病。杰伊及其同事的一项新研究是首次大型病例对照研究，直接检查了动脉粥样硬化性心血管疾病患者与对照个体相比，肠道细菌某些群落的富集情况。
相似文献
1
Atherosclerosis: Association between the gut microbiome and atherosclerosis.动脉粥样硬化：肠道微生物组与动脉粥样硬化的关联。
Nat Rev Cardiol. 2017 Dec;14(12):699-700. doi: 10.1038/nrcardio.2017.169. Epub 2017 Nov 3.
2
Metagenomics, culturomics, and the human gut microbiota.宏基因组学、培养组学与人类肠道微生物群
Expert Rev Anti Infect Ther. 2018 May;16(5):373-375. doi: 10.1080/14787210.2018.1467268. Epub 2018 Apr 23.
3
Role of gut microbiota in atherosclerosis.肠道微生物群在动脉粥样硬化中的作用。
Nat Rev Cardiol. 2017 Feb;14(2):79-87. doi: 10.1038/nrcardio.2016.183. Epub 2016 Dec 1.
4
The gut microbiome in atherosclerotic cardiovascular disease.动脉粥样硬化性心血管疾病中的肠道微生物群
Nat Commun. 2017 Oct 10;8(1):845. doi: 10.1038/s41467-017-00900-1.
5
[Impact of newly developed metagenomic tools on our knowledge of the gut microbiota and its role in human health: diagnostic and therapeutic issues].[新开发的宏基因组学工具对我们关于肠道微生物群及其在人类健康中的作用的认识的影响：诊断和治疗问题]
Med Sci (Paris). 2016 Nov;32(11):944-951. doi: 10.1051/medsci/20163211009. Epub 2016 Dec 23.
6
Intestinal Microbiota Metabolism and Atherosclerosis.肠道微生物群代谢与动脉粥样硬化
Chin Med J (Engl). 2015 Oct 20;128(20):2805-11. doi: 10.4103/0366-6999.167362.
7
Antibiotics as both friends and foes of the human gut microbiome: The microbial community approach.抗生素既是人类肠道微生物组的朋友，也是其敌人：微生物群落方法。
Drug Dev Res. 2019 Feb;80(1):86-97. doi: 10.1002/ddr.21466. Epub 2018 Oct 28.
8
Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis.定量宏基因组学揭示强直性脊柱炎中独特的肠道微生物组生物标志物。
Genome Biol. 2017 Jul 27;18(1):142. doi: 10.1186/s13059-017-1271-6.
9
Human Gut Microbiome: Function Matters.人类肠道微生物组：功能至关重要。
Trends Microbiol. 2018 Jul;26(7):563-574. doi: 10.1016/j.tim.2017.11.002. Epub 2017 Nov 22.
10
Social behavior and the microbiome.社会行为与微生物群
Elife. 2015 Mar 31;4:e07322. doi: 10.7554/eLife.07322.
引用本文的文献
1
2
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach.靶向前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）治疗中枢神经系统疾病：作为一种有前景方法的作用
Eur J Med Res. 2025 Jul 30;30(1):690. doi: 10.1186/s40001-025-02937-1.
3
Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE mice.负载依洛尤单抗和姜黄素的仿生纳米复合物用于ApoE小鼠的协同抗动脉粥样硬化治疗
J Nanobiotechnology. 2025 Jun 3;23(1):412. doi: 10.1186/s12951-025-03444-5.
4
Molecular Mechanisms and Emerging Precision Therapeutics in the Gut Microbiota-Cardiovascular Axis.肠道微生物群-心血管轴的分子机制与新兴精准疗法
Cureus. 2025 Apr 26;17(4):e83022. doi: 10.7759/cureus.83022. eCollection 2025 Apr.
5
Ferroptosis, pathogenesis and therapy in AS co-depression disease.动脉粥样硬化合并抑郁症中的铁死亡、发病机制与治疗
Front Pharmacol. 2025 Feb 24;16:1516601. doi: 10.3389/fphar.2025.1516601. eCollection 2025.
6
Fecal bacteria transplantation replicates aerobic exercise to reshape the gut microbiota in mice to inhibit high-fat diet-induced atherosclerosis.粪便细菌移植可复制有氧运动，重塑小鼠肠道微生物群，以抑制高脂饮食诱导的动脉粥样硬化。
PLoS One. 2025 Feb 4;20(2):e0314698. doi: 10.1371/journal.pone.0314698. eCollection 2025.
7
Effects of Artemisia asiatica ex on Akkermansia muciniphila dominance for modulation of Alzheimer's disease in mice.青蒿提取物对阿克曼氏菌属优势度的影响及其对阿尔茨海默病的调节作用。
PLoS One. 2024 Oct 28;19(10):e0312670. doi: 10.1371/journal.pone.0312670. eCollection 2024.
8
Impact of the gut microbiome on atherosclerosis.肠道微生物群对动脉粥样硬化的影响。
mLife. 2024 Apr 1;3(2):167-175. doi: 10.1002/mlf2.12110. eCollection 2024 Jun.
9
From heart to gut: Exploring the gut microbiome in congenital heart disease.从心脏到肠道：探索先天性心脏病中的肠道微生物群
Imeta. 2023 Oct 30;2(4):e144. doi: 10.1002/imt2.144. eCollection 2023 Nov.
10
Pleiotropic activities of succinate: The interplay between gut microbiota and cardiovascular diseases.琥珀酸的多效性活动：肠道微生物群与心血管疾病之间的相互作用
Imeta. 2023 Jun 19;2(3):e124. doi: 10.1002/imt2.124. eCollection 2023 Aug.
本文引用的文献
1
The gut microbiome in atherosclerotic cardiovascular disease.动脉粥样硬化性心血管疾病中的肠道微生物群
Nat Commun. 2017 Oct 10;8(1):845. doi: 10.1038/s41467-017-00900-1.
2
Gut Microbiota and Atherosclerosis.肠道微生物群与动脉粥样硬化。
Curr Atheroscler Rep. 2017 Aug 25;19(10):39. doi: 10.1007/s11883-017-0675-9.
3
Role of gut microbiota in atherosclerosis.肠道微生物群在动脉粥样硬化中的作用。
Nat Rev Cardiol. 2017 Feb;14(2):79-87. doi: 10.1038/nrcardio.2016.183. Epub 2016 Dec 1.
4
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk.肠道微生物代谢产物氧化三甲胺增强血小板高反应性和血栓形成风险。
Cell. 2016 Mar 24;165(1):111-124. doi: 10.1016/j.cell.2016.02.011. Epub 2016 Mar 10.
5
Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis.肠道微生物三甲胺生成的非致死性抑制用于动脉粥样硬化的治疗
Cell. 2015 Dec 17;163(7):1585-95. doi: 10.1016/j.cell.2015.11.055.
6
Personalized Nutrition by Prediction of Glycemic Responses.基于血糖反应预测的个性化营养。
Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001.
7
Unraveling the environmental and genetic interactions in atherosclerosis: Central role of the gut microbiota.解析动脉粥样硬化中的环境与基因相互作用：肠道微生物群的核心作用
Atherosclerosis. 2015 Aug;241(2):387-99. doi: 10.1016/j.atherosclerosis.2015.05.035. Epub 2015 Jun 3.
8
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.肠道微生物对磷脂酰胆碱的代谢与心血管风险
N Engl J Med. 2013 Apr 25;368(17):1575-84. doi: 10.1056/NEJMoa1109400.
9
The impact of the gut microbiota on human health: an integrative view.肠道微生物群对人类健康的影响：综合观点。
Cell. 2012 Mar 16;148(6):1258-70. doi: 10.1016/j.cell.2012.01.035.
Zotero 插件